|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/18 | (2006.01) |
| G01N 33/577 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 3042917 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15196358.4 |
| Date of filing the European patent application | 2011-08-09 | |
| (97) | Date of publication of the European application | 2016-07-13 |
| (45) | Date of publication and mention of the grant of the patent | 2018-02-21 |
| (46) | Date of publication of the claims translation | 2018-05-10 |
| (30) | Number | Date | Country code |
| 373026 P | 2010-08-12 | US |
| (72) |
Demattos, Ronald, US
Lu, Jirong, US
Tang, Ying, US
|
| (73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Antikūnai prieš N3pGlu beta amiloidinį peptidą ir jų panaudojimas |
| ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-07-23 | 15 | 289.00 EUR |
| 2026-08-09 |